{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:27:33Z","timestamp":1776954453418,"version":"3.51.4"},"reference-count":50,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.205502","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:59:28Z","timestamp":1707152368000},"source":"Crossref","is-referenced-by-count":1,"title":["Identification of an angiogenesis-related risk score model for survival prediction and immunosubtype screening in multiple myeloma"],"prefix":"10.18632","author":[{"given":"Manya","family":"Yu","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongquan","family":"Ming","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Xia","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Fu","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Quality Control, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma.","volume":"1","author":"Storrs","year":"2021","journal-title":"Nat Commun"},{"key":"2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.","volume":"4","author":"Linn","year":"2018","journal-title":"JAMA Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","article-title":"Angiogenesis in multiple myeloma.","volume":"4","author":"Sezer","year":"2006","journal-title":"Eur J Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.","volume":"10","author":"Rajkumar","year":"2004","journal-title":"Blood"},{"key":"5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/ijms19072031","article-title":"New Insights in Anti-Angiogenesis in Multiple Myeloma.","volume":"1","author":"Vacca","year":"2018","journal-title":"Int J Mol Sci"},{"key":"6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.","volume":"1","author":"Vajkoczy","year":"2004","journal-title":"FASEB J"},{"key":"7","doi-asserted-by":"publisher","first-page":"E3119","DOI":"10.1073\/pnas.1216078109","article-title":"Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.","volume":"10","author":"Lussiez","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?","volume":"2","author":"Duda","year":"2017","journal-title":"Angiogenesis"},{"key":"9","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy.","volume":"7","author":"Jain","year":"2013","journal-title":"Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.","volume":"3","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/2326-6066.CIR-14-0244","article-title":"Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.","volume":"3","author":"Karam","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: cancer and other tales.","volume":"1","author":"Coukos","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.","volume":"2","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nprot.2016.017","article-title":"Optimization of drug combinations using Feedback System Control.","volume":"1","author":"Ho","year":"2016","journal-title":"Nat Protoc"},{"key":"15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/2472630316682338","article-title":"Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders.","volume":"2","author":"Nowak-Sliwinska","year":"2017","journal-title":"SLAS Technol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.","volume":"10","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1038\/ncomms12050","article-title":"Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.","volume":"7","author":"Stephens","year":"2016","journal-title":"Nat Commun"},{"key":"18","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer.","volume":"2","author":"Koeffler","year":"2018","journal-title":"Genome Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"e0245264","DOI":"10.1371\/journal.pone.0245264","article-title":"Enhancing web search result clustering model based on multiview multirepresentation consensus cluster ensemble (mmcc) approach.","volume":"1","author":"Taha","year":"2021","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/omi.2009.0083","article-title":"ConsensusCluster: a software tool for unsupervised cluster discovery in numerical data.","volume":"1","author":"Bhanot","year":"2010","journal-title":"OMICS"},{"key":"21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data.","volume":"1","author":"Guinney","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/s0093-7754(01)90023-5","article-title":"Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.","volume":"2","author":"Bellamy","year":"2001","journal-title":"Semin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.09.022","article-title":"Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.","volume":"15","author":"John","year":"2020","journal-title":"Lung Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","article-title":"A practical guide to understanding Kaplan-Meier curves.","volume":"14","author":"Wang","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"key":"25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.","volume":"1","author":"Trajanoski","year":"2017","journal-title":"Cell Rep"},{"key":"26","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/carcin\/bgaa037","article-title":"Genotype-immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma.","volume":"4","author":"Liu","year":"2020","journal-title":"Carcinogenesis"},{"key":"27","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"4","author":"Smyth","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"1","author":"He","year":"2012","journal-title":"OMICS"},{"key":"29","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.1038\/s41598-018-33911-z","article-title":"Prediction of high anti-angiogenic activity peptides in silico using a generalized linear model and feature selection.","volume":"8","author":"Fernandez-Lozano","year":"2018","journal-title":"Sci Rep"},{"key":"30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.","volume":"55","author":"Yang","year":"2018","journal-title":"Nature"},{"key":"31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma.","volume":"26","author":"Ghobrial","year":"2015","journal-title":"Immunol Rev"},{"key":"32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.leu.2404067","article-title":"Bone marrow angiogenesis in multiple myeloma.","volume":"2","author":"Ribatti","year":"2006","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The Intersection between Tumor Angiogenesis and Immune Suppression.","volume":"2","author":"Hodi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma.","volume":"13","author":"Hill","year":"2020","journal-title":"J Clin Invest"},{"key":"35","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.","volume":"2","author":"Hideshima","year":"2015","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/hematology.2019000068","article-title":"Myeloma: next generation immunotherapy.","volume":"201","author":"Cohen","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4161\/cbt.11.1.13878","article-title":"Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack.","volume":"1","author":"Cai","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-022-02363-9","article-title":"CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.","volume":"4","author":"Simonetti","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.","volume":"12","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.","volume":"9","author":"Frassanito","year":"2020","journal-title":"Cells"},{"key":"41","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-13-0039","article-title":"Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.","volume":"1","author":"Ruggieri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-14-0847","article-title":"A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.","volume":"2","author":"Rizzello","year":"2014","journal-title":"Clin Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.","volume":"24","author":"Nico","year":"2019","journal-title":"J Pathol"},{"key":"44","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1002\/cam4.4221","article-title":"Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma.","volume":"1","author":"Chen","year":"2021","journal-title":"Cancer Med"},{"key":"45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy.","volume":"1","author":"Fu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.","volume":"3","author":"Chapuy","year":"2016","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/10428194.2017.1320713","article-title":"Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.","volume":"5","author":"Lesokhin","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.17282","article-title":"Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.","volume":"19","author":"Huang","year":"2021","journal-title":"Br J Haematol"},{"key":"49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.","volume":"2","author":"Klein","year":"2012","journal-title":"Leukemia"},{"key":"50","doi-asserted-by":"publisher","first-page":"e14502","DOI":"10.15252\/emmm.202114502","article-title":"Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.","volume":"1","author":"Luan","year":"2022","journal-title":"EMBO Mol Med"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:59:31Z","timestamp":1707152371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":50,"alternative-id":["205502"],"URL":"https:\/\/doi.org\/10.18632\/aging.205502","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}